Hjem › Myelodysplastiske syndromer › Ohio
Myelodysplastiske syndromer kliniske forsøg i Ohio
22 studier for Myelodysplastiske syndromer søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT05320198A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Cleveland clinic OH, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT07422480Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
RekruttererObservationsstudie
2 Months · Alle køn · Opdateret 16. sep. 2026 · NCT00900198Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT03471260Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Ohio State University, The James Comprehensive Cancer, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- og 3 flere
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic - Cleveland, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06499285Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 10. aug. 2026 · NCT05308264A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Canton
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. jun. 2026 · NCT068478675-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 18. maj 2026 · NCT04187703A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT04256317Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- Ohio State University Medical Center, Columbus
RekruttererFase 1
Alder 18 til 65 · Alle køn · Opdateret 25. mar. 2026 · NCT03533816A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 24. mar. 2026 · NCT04988555Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Cleveland Clinic Cancer Center, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. mar. 2026 · NCT06543381HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
RekruttererFase 2
3 Months · Alle køn · Opdateret 12. nov. 2025 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2025 · NCT06501196HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
RekruttererObservationsstudie
Alder 12 til 80 · Alle køn · Opdateret 28. aug. 2025 · NCT07145411Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.